Business News

NVIDIA (NVDA) announces a collaboration with Novo Nordisk

Nvidia Corporation (Nasdaq: NVDA) is one of the 10 best semiconductor actions to buy according to Reddit. NVIDIA Corporation (NASDAQ: NVDA) has announced collaboration with Novo Nordisk to increase drug discovery efforts via innovative AI use cases. The work supports the Novo Nordisk agreement with DCAI to use the sovereign Supercalculator of Gefion Sovereign. Companies focus on creating personalized AI models and agents that Novo Nordisk can use for early research and clinical development, as well as to apply advanced simulation and physical AI technologies. The Gefion de DCAI Supercalculator, which is propelled by Nvidia DGX Superpod â„¢, offers Novo Nordisk an AI factory to run the discovery of drugs and the original workloads.

NVIDIA (NVDA) announces a collaboration with Novo Nordisk

A close -up of a high -end colorful graphics card being connected to a game computer.

Elsewhere, Morningstar estimates that NVIDIA Corporation DC activities (NASDAQ: NVDA) have reached exponential growth, from $ 3 billion during the year 2020 to 115 billion dollars during the year 2025. The firm estimates that DC income remains forced to offer, with short -term income that should increase as more online supply. The company has allocated NVIDIA Corporation (NASDAQ: NVDA) a large economic ditch, resulting from intangible assets linked to its graphic processing units and switching costs associated with its owner software, such as its CUDA platform for the creation of AI tools, which tends to allow the developers to use the GPU models of NVIDIA to create AI models.

Longriver Investment Partners has published its letter as an investor of the T2 2025. Here is what the fund said:

“This change in the priorities of the CAPEX has reopened the debate on calculation architectures. Personalized silicon promises a way to get out of NVIDIA Corporation (Nasdaq: NVDA) The power of pricing, in particular for inference. But the path is not simple.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button